Additionally, prior therapies might influence PD-L1 expression: A study by McDaniel et al. demonstrated a significant increase in PD-L1 expression in patients with urothelial carcinoma following neoadjuvant cytotoxic chemotherapy [30]. Here, CD274 is linked to urothelial carcinoma.